Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  Relief therapeutics  /  Relief therapeutics Holding

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel RELIEF THERAPEUTICS N ZSE:RLF.CH, CH1251125998

  • 1,260 18 apr 2024 17:18
  • +0,045 (+3,70%) Dagrange 1,200 - 1,325
  • 25.907 Gem. (3M) 15,2K

Relief therapeutics Holding

9.103 Posts
Pagina: «« 1 ... 145 146 147 148 149 ... 456 »» | Laatste | Omlaag ↓
  2. [verwijderd] 23 september 2020 08:32
    www.srf.ch/news/schweiz/das-neuste-zu...

    7:49
    Schweizer Pharmafirmen beantragen in den USA «Notfallzulassung» für eine Arznei

    Die Schweizer Pharmafirma Relief Therapeutics und ihr Partner NeuroRx haben in den USA die Notfallzulassung eines experimentellen Coronavirus-Medikaments beantragt. Die Arznei soll bei Patienten mit Covid-19 in einem kritischen Stadium zum Einsatz kommen, die alle zugelassenen Therapien ausgeschöpft haben. Der Zulassungsantrag bei der US-Arzneimittelbehörde FDA basiert auf einer Fall-Kontroll-Studie. Relief zufolge zeigten Patienten auf der Intensivstation bei einer Behandlung mit dem neuen Medikament bessere Ergebnisse hinsichtlich Erholung von Atemversagen und Überleben als bei einer Standardtherapie.

    Zwitserse TV over Relief.
  4. Hangyodon 23 september 2020 08:51
    www.marketscreener.com/quote/stock/RE...

    Relief Therapeutics : partner NeuroRx submits request for Emergency Use Authorization for RLF-100(TM) (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy
    share with twitter share with LinkedIn share with facebook


    0
    09/23/2020 | 01:05am EDT

    EQS Group-News: Relief Therapeutics Holdings AG / Key word(s): Miscellaneous
    Relief partner NeuroRx submits request for Emergency Use Authorization for RLF-100(TM) (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy

    23.09.2020 / 07:02

    Relief partner NeuroRx submits request for Emergency Use Authorization for RLF-100(TM) (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy

    Emergency Use Authorization request targets the same population as is currently permitted under FDA Expanded Access Protocol

    Geneva, Switzerland, and Radnor, PA, September 23, 2020 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company") and NeuroRx, Inc. today announce that NeuroRx, Inc. has submitted a request for an Emergency Use Authorization (EUA) with the US FDA for the use of RLF-100(TM) aviptadil in patients who are receiving intensive care and who have exhausted all approved treatments. RLF-100 is being developed by NeuroRx as part of a global partnership with Relief. The submission is based on a case-control study that compared patients who were treated with RLF-100(TM) (n=21) to those receiving maximal standard of care treatment (n=30) in the same ICU by the same medical staff. Patients treated with RLF-100(TM) demonstrated a 3-fold advantage in survival, recovery from respiratory failure, and other parameters indicative of meaningful clinical improvement. Hypotension was seen in two aviptadil patients and was successfully managed with pressors. Diarrhea was seen in 4/21 aviptadil-treated patients and 3/30 control patients. The results have been submitted to a peer-reviewed journal.

    "The EUA application covers the same type of patients whom FDA has already allowed to receive treatment under the Expanded Access protocol authorized by the Agency in July. Tragically, we have found that many patients who might benefit from the Expanded Access protocol are hospitalized in centers that do not allow patients access to investigational drugs," said Jonathan Javitt, MD, MPH, Chairman and CEO of NeuroRx, "Our staff is working around the clock to address requests for RLF-100(TM) under the appropriate mechanism. All too often, patients of color and those of lower socioeconomic status are denied access."

    FDA's guidance to industry identifies the criteria for EUA as safe and "may be effective," in contrast to the far more stringent requirement of "safe and effective" required for traditional drug approval. EUA may only be granted in circumstances where the Secretary of Health and Human Services has declared a Public Health Emergency, as is true in the COVID-19 pandemic.

    Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, said: "We continue to work tirelessly with our partner NeuroRx to bring this potentially life-saving drug to patients afflicted with severe complications of COVID-19 infection as quickly as possible. The pursuit of EUA status is a crucial component of this effort."

    About VIP in Lung Injury
    Vasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970. Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and to be primarily concentrated in the lungs. VIP has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, 70% of the VIP in the body is bound to a rare cell in the lung, the alveolar type 2 cell, which is critical to the transmission of oxygen to the body. VIP has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension.

    COVID-19-related death is primarily caused by Respiratory Failure. Before this acute phase, however, there is evidence of early viral infection of the alveolar type 2 cells. These cells are known to have angiotensin converting enzyme 2 (ACE2) receptors at high levels, which serve as the route of entry for the SARS-CoV-2 into the cells. Coronaviruses are shown to replicate in alveolar type 2 cells, but not in the more numerous type 1 cells. These same type 2 alveolar cells have high concentrations of VIP receptors on their cell surfaces giving rise to the hypothesis that VIP could specifically protect these cells from injury.

    Injury to the type 2 alveolar cells is an increasingly plausible mechanism of COVID-19 disease progression. (Mason 2020). These specialized cells replenish the more common type 1 cells that line the lungs. More importantly, type 2 cells manufacture surfactant that coats the lung and is essential for oxygen exchange. Other than RLF-100, no currently proposed treatments for COVID-19 specifically target these vulnerable type 2 cells.

    About RLF-100
    RLF-100 (Aviptadil) is a formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Said's original work at Stony Brook University, for which Stony Brook was awarded an FDA Orphan Drug Designation in 2001. VIP is known to be highly concentrated in the lungs, where it inhibits coronavirus replication, blocks the formation of inflammatory cytokines, prevents cell death, and upregulates the production of surfactant. FDA has now granted IND authorization for intravenous and inhaled delivery of RLF-100 for the treatment of COVID-19 and awarded Fast Track designation. RLF-100 is being investigated in two placebo-controlled US Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Since July 2020, severe COVID-19 patients have been treated with RLF-100 under U.S. FDA Emergency Use Investigational New Drug (IND) authorization for treatment of individual patients, and an Expanded Access Protocol IND authorization for the treatment of respiratory failure in COVID-19.
  7. forum rang 6 Chiddix 23 september 2020 09:07
    quote:

    Bert-Jan schreef op 22 september 2020 12:30:

    [...]

    Heb je je ooit inhoudelijk verdiept in dit aandeel? Hoe kom je aan het getal van 5 miljoen?
    Nee, ik ken dit aandeel niet maar elke keer als ik wat wil schrijven in het coronavirusdraadje kijk ik tegen dit draadje aan. De FDA moet dus zijn goedkeuring nog geven. Als ik goed lees zijn er twee partijen voor de medicatie. Moeten die de opbrengst delen bij goedkeuring?
  9. Hangyodon 23 september 2020 09:16
    quote:

    Chiddix schreef op 23 september 2020 09:07:

    [...]

    Nee, ik ken dit aandeel niet maar elke keer als ik wat wil schrijven in het coronavirusdraadje kijk ik tegen dit draadje aan. De FDA moet dus zijn goedkeuring nog geven. Als ik goed lees zijn er twee partijen voor de medicatie. Moeten die de opbrengst delen bij goedkeuring?
    ik ga niet zeggen van delen. de een gaat USA regelen en de anderen EU en daar krijgen ze ieder een klein stuk ervan.

  10. forum rang 10 DeZwarteRidder 23 september 2020 09:18
    quote:

    Chiddix schreef op 23 september 2020 09:07:

    [...]Nee, ik ken dit aandeel niet maar elke keer als ik wat wil schrijven in het coronavirusdraadje kijk ik tegen dit draadje aan. De FDA moet dus zijn goedkeuring nog geven. Als ik goed lees zijn er twee partijen voor de medicatie. Moeten die de opbrengst delen bij goedkeuring?
    Relief krijgt hoogstens ca 25% van de bruto omzet.

    Iedereen wil meeprofiteren en Relief heeft geen personeel.
9.103 Posts
Pagina: «« 1 ... 145 146 147 148 149 ... 456 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!